Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Ziopharm Oncology Presentation at the 38th Annual J.P. Morgan Healthcare Conference to be Webcast
BOSTON , Dec. 19, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP), today announced that Laurence Cooper , M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to make a webcast presentation at the 38 th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday,
View HTML
Toggle Summary Ziopharm Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BOSTON , Dec. 09, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP) today reported that the Company granted a new employee an option to purchase an aggregate of 65,000 shares of Ziopharm’s common stock effective November 21, 2019 .
View HTML
Toggle Summary Ziopharm Oncology Presents Pre-Clinical Data Validating “Rapid Personalized Manufacture” (RPM) with TCR at the 2019 American Society for Hematology Annual Meeting
– Membrane bound IL-15 (mbIL15) improves anti-tumor effect of TCR-modified T cells – – T cells expressing T-cell receptor (TCR) and mbIL15 can be infused day after gene transfer – BOSTON , Dec. 08, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or the “Company”) (Nasdaq:ZIOP), today
View HTML
Toggle Summary Ziopharm Oncology Presents Encouraging Clinical Data for Controlled IL-12 for the Treatment of Recurrent Glioblastoma at the 2019 Society for Neuro-Oncology Annual Meeting
– Controlled IL-12 evaluated as monotherapy in an expanded number of patients reinforced favorable safety profile and initial data consistent with immune-mediated anti-tumor effects – – Controlled IL-12 can be combined with full dose of a PD-1 inhibitor; favorable safety profile and initial data
View HTML
Toggle Summary Ziopharm Oncology Updates Presentation and Webcast Time at the Jefferies 2019 London Healthcare Conference
Presentation moved to 1:20 p.m. GMT (8:20 a.m. ET) on November 20, 2019 BOSTON , Nov. 18, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq: ZIOP) today announced that the Company’s presentation at the Jefferies 2019 London Healthcare Conference on November 20, 2019 , has been moved to 1:20
View HTML
Toggle Summary Ziopharm Oncology Presentation at the Jefferies 2019 London Healthcare Conference to be Webcast
BOSTON , Nov. 11, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq: ZIOP) today announced that Laurence Cooper , M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to make a webcast presentation at the Jefferies 2019 London Healthcare Conference on November 20, 2019 , beginning
View HTML
Toggle Summary Ziopharm Oncology Reports Third Quarter 2019 Financial Results
– Phase 2 trial of Sleeping Beauty TCR-T cell therapy for  patients with solid tumors initiated at the National Cancer Institute (NCI) – – New agreement with MD Anderson Cancer Center to expand library of T-cell receptors (TCRs) targeting neoantigens; Enables new clinical trials – – Balance sheet
View HTML
Toggle Summary Ziopharm Oncology to Host Conference Call to Discuss Third Quarter 2019 Results on November 7, 2019
BOSTON , Oct. 30, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP) today announced that management will host a conference call and webcast on Thursday, November 7 , at 4:30 p.m. ET to provide a corporate update and discuss financial results for the third quarter ended September 30 ,
View HTML
Toggle Summary Ziopharm Oncology and MD Anderson Cancer Center Announce New R&D Agreement to Expand TCR-T Program
–  Accelerates capability for TCR library expansion of T-cell receptors (TCRs) targeting neoatigens, including in hotspots –              – Enables two new TCR-T clinical trials at MD Anderson leveraging the Sleeping Beauty non-viral gene transfer platform – – New lease for larger facility allows
View HTML
Toggle Summary Ziopharm Oncology Names Drug Development Leader Dr. Chris Bowden to Board of Directors
– Industry veteran with 20+ years of global oncology drug development leadership –   – Current CMO at Agios Pharmaceuticals ; Former VP of Product Development, Oncology at Genentech –   BOSTON , Oct. 15, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP),
View HTML